Co-Authors
This is a "connection" page, showing publications co-authored by YING YUAN and AUNG NAING.
Connection Strength
0.754
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.244
-
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8).
Score: 0.235
-
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel). 2022 Jul 29; 14(15).
Score: 0.219
-
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
Score: 0.056